1. Pink Sheet
  2. >>R&D

India Clinical Trials Scenario: Leaders From Novartis, IQVIA, PwC Signal Winds Of Change

 
• By Anju Ghangurde

Leaders from Novartis, IQVIA and PwC discuss the ground situation for trials in India as regulatory reforms, improved infrastructure and clinical expertise provide opportunities. Potential in areas like orphan diseases and tips for peer Amgen on getting trials going in India were among other highlights.

India's clinical trials segment provides opportunities • Source: Shutterstock

If you’re entering India for clinical trials, then don’t do it half-heartedly, just 'go all in', but be careful about the initial choice of disease areas – that’s the advice Novartis’s head, global clinical operations, Badhri Srinivasan had for his peer at Amgen, Inc. which appears to be evaluating opportunities in the world's most populous country.

Responding to a question from Amgen’s senior vice president, global development, Rob Lenz at a recent summit, Srinivasan said that while a number of companies have dipped their toes in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By Vibha Sharma

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A

 
• By Neena Brizmohun

Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.

Europe’s UPC Issues Landmark Ruling On Second Medical Use Claims

 
• By Neena Brizmohun

The verdict by the Unified Patent Court in the dispute between Sanofi/Regeneron Pharmaceuticals and Amgen explains what companies should look out for when deciding whether infringement has taken place when it comes to second medical use patents.